Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Dr.
Pritchard: The good thing is that coming in every month and getting
the injection is not a big problem. It’s a 5 cc injection,
which for some reason terrorized everybody in the beginning, and
we actually gave it in split doses, intramuscular injection. But
in fact, you can give 5 cc’s or 2.5 cc’s twice and neither
of them cause much in the way of local problems at all. It’s
very well tolerated. It’s an injection but it doesn’t
seem to be a big problem. I guess if this drug gets moved into the
adjuvant setting, that could be more of an issue, but in the metastatic
setting it doesn’t seem to be an issue for our patients at
all. We’ve had some experience in the adjuvant setting using
another injectable over a five year period, and actually once you
get the mechanisms in place, it doesn’t seem to be a big issue.
So, that’s as much as I can tell you about side effects of
Faslodex, is the piece about the injections. We can’t tell
which are the Faslodex injections and which are the placebo injections
either so….
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
